Company news
Luye Pharma Group Ltd. news in 2026
Luye Pharma Group Ltd.'s news releases, calls and decks from 2026, newest first.
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 7, 2026
Interim Report 2026
September 29, 2026
Luye Pharma Announces 2026 Interim Results
September 1, 2026
Luye Pharma Announces Successful Completion of a U.S. Bridging Clinical Trial of Its Innovative Drug LY03015 (VMAT2 Inhibitor/Sigma-1R...
August 5, 2026
Luye Pharma Announces Positive Phase 2 Results of LY03015, a VMAT2 Inhibitor and Sigma-1R Agonist, for Tardive Dyskinesia in China
June 16, 2026
Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015
April 21, 2026
First Subject Enrolled in Phase Ⅱ Clinical Trial of Luye Pharma’s TAAR1/5-HT2CR-targeted Investigational Drug for Treating...
April 8, 2026
NMPA Accepts the NDA for Luye Pharma’s Ruoxinlin® for the New Indication of Generalized Anxiety Disorder
January 8, 2026